AcelRx names Richard King as president, CEO

> AcelRx Pharmaceuticals has named Richard King as president and CEO. Release

> Entest BioMedical has hired Tammy Reynolds as its new CFO. Release

> BIO Ventures for Global Health has announced that Donald Joseph has been named COO and a member of the board of directors.  Release

> PharmAthene has tapped Thomas Fuerst as the company's SVP, chief scientific officer. Release

> Inhibitex has announced that John Alam has joined the company as its senior medical advisor. Release

> Idera Pharmaceuticals has appointed of Robert Arbeit, as VP of clinical development, and Nicola La Monica as VP of biology. It also promoted Timothy Sullivan, VP of development programs, to VP of development programs and alliance management. Release

> ZIOPHARM Oncology has appointed George Abercrombie, former president and CEO of Hoffmann-La Roche North America to its board of directors. Additionally, Murray Brennan was elected chairman of the board. Release

> Novavax has named James Young to its board of directors. He was previously president of R&D at MedImmune  Release

Suggested Articles

Preclinical-stage biotech Abpro Therapeutics wants to trial its two lead candidates for HER2-positive cancers and diabetic macular edema in 2019.

After a rough patch in 2017, the stars seem to be realigning for French CAR-T expert Cellectis, which just closed a $164 million U.S. public offering.

Investment firm Frazier Healthcare Partners has closed its 11th fund—worth $780 million—that will help established companies accelerate their growth.